Pulsed Field Ablation Reduces Recurrence in Persistent Atrial Fibrillation

First-line pulsed field ablation showed a 56% success rate at 12 months compared to 30% for antiarrhythmic drugs in a randomized trial.

For Doctors in a Hurry

Current guidelines recommend antiarrhythmic drugs before catheter ablation, but the efficacy of initial pulsed field ablation remains clinically uncertain.
This international trial randomized 310 patients with untreated persistent atrial fibrillation to receive either pulsed field ablation or drug therapy.
Treatment success occurred in 56% of the ablation group versus 30% of the drug group (hazard ratio, 0.46; P<0.001).
The researchers concluded that pulsed field ablation significantly reduces atrial arrhythmia recurrence when used as a first-line clinical intervention.
These findings suggest that early catheter ablation using pulsed field technology provides superior rhythm control compared to traditional medical management.

Rhythm Control Strategies in Persistent Atrial Fibrillation

Managing persistent atrial fibrillation remains a significant clinical challenge, as these patients often face lower success rates for long-term rhythm control compared to those with paroxysmal disease [1]. Current clinical guidelines generally recommend a trial of antiarrhythmic drugs as the initial step before proceeding to catheter-based interventions [2]. While thermal ablation techniques are established options for drug-refractory cases, they carry inherent risks of collateral damage to adjacent structures like the esophagus or phrenic nerve due to their reliance on extreme temperatures [3]. Pulsed field ablation has emerged as a nonthermal alternative that uses electrical fields to create tissue-selective lesions, a process that may offer a more favorable safety profile in the pulmonary veins and posterior wall [4]. The international, randomized AVANT GUARD trial now evaluates whether moving this technology to the front-line setting can improve outcomes for patients with previously untreated persistent atrial fibrillation, potentially altering how clinicians sequence rhythm-control therapies.

Trial Design and Continuous Monitoring Protocols

The AVANT GUARD trial enrolled patients with previously untreated persistent atrial fibrillation, a population that typically faces high recurrence rates under standard medical management. To compare early interventional and pharmacological strategies, researchers randomly assigned participants in a 2:1 ratio to receive either pulsed field ablation or conventional antiarrhythmic-drug therapy. For the intervention group, clinicians performed the procedure using a pentaspline catheter (a multi-electrode device that expands into a star-like shape to deliver targeted electrical pulses to the cardiac tissue). To broaden the safety data available for this technology, the study also included an additional non-randomized group of patients who underwent the procedure specifically for the analysis of the primary safety end point. To ensure rigorous detection of post-treatment arrhythmias, all patients in the trial received an insertable cardiac monitor for continuous rhythm surveillance. This use of a subcutaneously implanted monitor provided a more comprehensive assessment of treatment success than intermittent electrocardiograms or Holter monitoring, capturing even asymptomatic recurrences of atrial fibrillation throughout the 12-month follow-up period. (Funded by Boston Scientific; ClinicalTrials.gov number NCT06096337).

Defining Success in Ablation and Medical Therapy

To evaluate comparative efficacy, the researchers established a primary effectiveness end point that integrated both short-term and long-term treatment success through 12 months. Short-term success was defined differently for each cohort to reflect their respective treatment pathways. For the pulsed field ablation group, short-term success required achieving procedural success, defined as the acute isolation of the targeted pulmonary veins during the index procedure. In contrast, short-term success for the antiarrhythmic-drug group was defined as the absence of any catheter ablation during the 90-day blanking period (the three-month window following treatment initiation where transient arrhythmias are common and typically do not count as treatment failure). The criteria for long-term success also accounted for the distinct therapeutic goals of each arm. For patients in the pulsed field ablation group, long-term success required freedom from any recurrence of atrial arrhythmias, repeat ablation procedures, or the need for antiarrhythmic drugs from the end of the 90-day blanking period through the 12-month mark. This rigorous definition ensured that any late-stage recurrence or the necessity for supplemental pharmacological rhythm control would be classified as a treatment failure. For the antiarrhythmic-drug group, long-term success was defined as freedom from the use of amiodarone at any time during the study. This specific restriction on amiodarone (a potent but often poorly tolerated rhythm-control medication) reflects its clinical status as a second-line therapy due to its significant side-effect profile. For practicing physicians, these end points directly mirror the clinical goal of maintaining sinus rhythm without escalating to high-toxicity medications or repeat procedures.

Superiority of First-Line Ablation for Rhythm Maintenance

At the 12-month follow-up, the researchers observed a clear divergence in clinical outcomes between the two treatment arms. In the pulsed field ablation group, treatment success occurred in 128 of 207 patients, resulting in a Kaplan-Meier estimate (a statistical method used to calculate the probability of an event occurring over time) of 56% (95% confidence interval [CI], 48 to 63). By comparison, the antiarrhythmic-drug group demonstrated lower rates of rhythm maintenance, with treatment success occurring in 40 of 103 patients, yielding a Kaplan-Meier estimate of 30% (95% CI, 21 to 40). These figures represent the composite of procedural success and the absence of arrhythmia recurrence or medication escalation, providing a comprehensive view of long-term stability. The quantitative benefit of the interventional approach was further underscored by the analysis of treatment failure. The hazard ratio for composite treatment failure was 0.46 (95% CI, 0.33 to 0.65; P<0.001), indicating that patients receiving pulsed field ablation were substantially less likely to experience a lack of treatment success compared to those on medical therapy. Ultimately, the risk of recurrence of atrial arrhythmia was significantly lower among those who received pulsed field ablation as first-line treatment than among those who received antiarrhythmic-drug therapy. For the practicing clinician, these data suggest that early intervention with pulsed field ablation may offer a more effective path to maintaining sinus rhythm in the persistent atrial fibrillation population than the traditional trial of antiarrhythmic medications.

Safety Profile and Serious Adverse Events

The researchers defined the primary safety end point as device- and procedure-related serious adverse events, a metric designed to capture complications directly attributable to the pulsed field ablation technology or the intervention itself. In the combined pulsed field ablation group, which included both randomized patients and those specifically assigned to the ablation arm for safety analysis, a primary safety end-point event occurred in 13 of 257 patients (5.1%). This rate provides a baseline for the procedural risks associated with the pentaspline catheter when used as a first-line intervention for persistent atrial fibrillation, reflecting the immediate clinical trade-offs of an invasive approach. Beyond procedure-specific complications, the study tracked the broader incidence of serious adverse events through the first year of management to compare the overall safety of each strategy. At 12 months, serious adverse events had occurred in 45 patients (25%) in the pulsed field ablation group, while serious adverse events occurred in 20 patients (21%) in the antiarrhythmic-drug group. These figures encompass all significant clinical setbacks, including those unrelated to the procedure itself, such as medication toxicities or hospitalizations. For the practicing clinician, these safety data indicate that while pulsed field ablation carries a specific 5.1% risk of major procedural complications, the total burden of serious adverse events at one year is comparable to the 21% rate observed with conventional medical management, allowing physicians to weigh the higher efficacy of early ablation against its procedural risks.

Study Info

Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation

Oussama M. Wazni, K. R. Julian Chun, D Nair, Ante Anic, et al.

Journal New England Journal of Medicine

Published April 25, 2026